June 30, 2016 5:19pm
… The opening and closing bell were negative while the mid-day was positive
Don’t chase the tape, head-out to the July 4th holiday weekend and be SAFE
… An indication (?) as investors eye the end of Q2
My pre-open indications – 5 hits and 2 miss:
Do you care what happened today, you should … because it has implications to Friday's sector activity?
Where has today’s market gone – subscribe and find out.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. stocks closed higher Thursday in their third-straight day of recovery from the post-Brexit sell-off.
The NASDAQ closed UP +63.43 or +1.33% to 4,842.67 and the DOW closed UP +235.31 or +1.33% to 17,929.99.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 17/21 and 5 flat;
- The mid-day flipped positive with an A/DL of 25/17 and 1 flat;
- The closing bell was barely negative with A/DL of 20/21 and 2 flats;
Henry’omics:
The SCGT&RT sector opened positive, stayed positive at the mid-day and closed negative.
- Abused and skeptical investors are looking for light at the end of the Q2 tunnel.
That is pretty questionable odds, as once financial results/ earnings are announced – the real “BLEED” of operating spending will be recognized.
- We are just digesting and retracing the Brexit retreat and now need to prepare for another …
My biggest role of the long weekend will be taking a deep breath to blow out the candles on the cake …
Review my fear gauge or the CBOE Volatility Index (VIX):
- Thursday traded near 16;
- Wednesday traded below 17;
- Tuesday traded near 20;
- Monday traded below 24;
- Friday traded above 23;
- Last, Thursday traded 17.4;
The Bottom Line:
The SCG&RT sector is breathing a big sigh of relief but, taking a deep breath as Q3 begins tomorrow.
My pre-open indications – 5 hits and 2 miss:
- Applied Genetic Technologies (AGTC) closed DOWN -$0.11 – hit;
- BioLife Solutions (BLFS) closed DOWN -$0.01 – hit;
- bluebird bio (BLUE) closed UP +$1.06 – hit;
- Fibrocell (FCSC) closed UP +$0.02 – miss;
- Juno therapeutics (JUNO) closed DOWN -$1.13 – hit;
- Kite Pharma (KITE) closed DOWN -$0.99 – hit;
- Mesoblast (MESO) closed DOWN -$0.06 – miss;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
